HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
Summary: Treatment-Naive Genotype 3 With Compensated Cirrhosis
Recommended and alternative regimens listed by pangenotypic,evidence level and alphabetically for:
Treatment-Naive Genotype 3 Patients With Compensated Cirrhosisa
RECOMMENDED
DURATION
RATING
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for patients without baseline NS5A RAS Y93H
12 weeks
I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b
8 weeks
I, B
ALTERNATIVE
DURATION
RATING
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) with weight-based ribavirin for patients with baseline NS5A RAS Y93H
12 weeks
IIa, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) for patients with baseline NS5A RAS Y93H
12 weeks
IIa, B
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.
